PREVENT Cancer Program (PREVENT)

The PREVENT Cancer Program is a Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH). This contract vehicle supports preclinical research focused on developing and evaluating potential cancer preventive agents, vaccines, and interventions through detailed efficacy studies and biomarker identification. The primary objective is to conduct preclinical research that can prevent the development of invasive cancers by testing and analyzing potential preventive strategies before they advance to clinical trials, with a particular emphasis on understanding pharmacodynamic efficacy and correlative biomarkers.

Task orders under this IDIQ consistently target specific cancer prevention research across various cancer types, including bladder, breast, colorectal, lung, pancreatic, and ovarian cancers. The delivery orders typically range from approximately $400,000 to $1,300,000, with performance periods spanning two to three years. Prime contractors frequently include academic medical research institutions such as the University of Alabama at Birmingham, University of Texas MD Anderson Cancer Center, Medical College of Wisconsin, and University of Oklahoma Health Sciences Center. The task orders consistently utilize firm fixed-price contracts and do not employ specific set-aside designations. Research is predominantly conducted at university research facilities, with a focus on preclinical efficacy testing, developing multi-antigen vaccines, evaluating potential chemopreventive agents, and identifying intermediate biomarkers that could correlate with cancer prevention strategies.